Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013
Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013
复制标题
成人急性髓性白血病和复发性遗传异常的发病率、生存率和危险因素：2001-2013 年监测、流行病学和最终结果 (SEER) 数据库分析
DOI：
10.1159/000486228
复制
发表时间：
2018-01-01
影响因子：
2.4
通讯作者：
Lan, Jianping
中科院分区：
文献类型：
--
作者：
Song, Xiaolu;Peng, Ye;Lan, Jianping
背景/目的：随着急性髓系白血病 (AML) 知识库的不断增长，分类系统已开始纳入这些新发现。方法：我们评估了 32,941 名 AML 患者，其记录包含在监测、流行病学和最终结果 (SEER) 数据库中。结果：2001 年至 2013 年间诊断的所有患者中有一半没有世界卫生组织 (WHO) 分类。急性早幼粒细胞白血病和急性全骨髓病伴骨髓纤维化与最长的白血病特异性生存期相关（分别为110个月和115个月），而具有最小分化的AML和急性巨核细胞白血病的生存期最短（分别为30个月和28个月）。对于 WHO 未明确说明的 AML (AML-NOS) 和复发性遗传异常 AML (AML-RGA) 组的患者，老年患者的死亡风险较高，已婚患者的死亡风险较低。患有任何类型 AML-NOS 的黑人患者的死亡风险也较高。与具有 WHO 类型 AML-NOS 的患者相比，未接受 WHO 分类的 AML 病例患者年龄较大，且该组患者的死亡风险较高。结论：我们的研究结果强调了 AML 患者的不同结局，以及使用 WHO 分类系统和人口因素来评估其预后的重要性。 (C) 2018 S. Karger AG，巴塞尔
Background/Aim: As the knowledgebase of acute myeloid leukemia (AML) has grown, classification systems have moved to incorporate these new findings. Methods: We assessed 32,941 patients with AML whose records are contained in the Surveillance, Epidemiology, and End Results (SEER) database. Results: Half of all patients diagnosed between 2001 and 2013 did not have a World Health Organization (WHO) classification. Acute promyelocytic leukemia and acute panmyelosis with myelofibrosis were associated with the longest leukemia-specific survival (110 and 115 months, respectively), and AML with minimal differentiation and acute megakaryoblastic leukemia with the shortest (30 and 28 months, respectively). For patients in the WHO groups AML not otherwise specified (AML-NOS) and AML with recur-rent genetic abnormalities (AML-RGA), the risk of death was greater for older patients and less for married patients. Black patients with any type of AML-NOS also had a higher risk of death. Patients whose case of AML did not receive a WHO classification were older and this group had a higher risk of death when compared to patients with a WHO type of AML-NOS. Conclusion: Our findings highlight the divergent outcomes of patients with AML and the importance of using the WHO classification system and demographic factors to gauge their prognosis. (C) 2018 S. Karger AG, Basel